GENOMIND, INC.
KING OF PRUSSIA, PA

Genomind, Inc., based in King of Prussia, PA, is an innovative leader in the field of genetic testing for mental health treatment optimization. Recognized as Philadelphia Business Journal's Emerging Company of the Year, Genomind offers The Genecept Assay®, a patented genetic test designed to assist clinicians in tailoring treatment plans for patients with mental illness. This cheek swab-based test analyzes patient-specific genetic markers to identify which treatments may be effective, ineffective, or cause adverse effects, thereby optimizing therapeutic outcomes. Founded by Dr. Ronald I. Dozoretz and Dr. Jay Lombard, the company employs a multidisciplinary team led by CEO Shawn O'Brien and President Kip Olmstead, with insights from notable figures like John Chadwick on its board of directors. With an eye toward commercialization since its incorporation in 2015 (Filed Number: F15000002171), Genomind continues to grow under the strategic leadership of experts in finance, operations, marketing, and scientific research. The company's commitment to precision medicine is evident in their dedication to developing technologies that advance personalized healthcare solutions. Genomind champions equal opportunity employment and maintains a drug-free workplace while providing competitive benefits packages to its staff. As they expand globally, the firm remains focused on integrating genetic insights with clinical care to improve mental health treatment paradigms. For more information about Genomind and its revolutionary contributions to psychopharmacology and biomarker testing in psychiatry, visit their official website at genomind.com.